Shaw Sorooshian has been appointed as Vice President and Chief Medical Officer of Moberg Pharma.
Shaw Sorooshian will during the fall be joining the management team at Moberg Pharma coming from a previous position as Senior Director Global Medical Affairs at Sobi AB. He will be replacing Kjell Rensfeldt in the management team, bringing extensive experience from his previous position as Senior Director Global Medical Affairs at Sobi AB (Swedish Orphan Biovitrum) as well as preceding senior positions at Shire, Lundbeck and Organon Laboratories.
Adding valuable experience
Shaw Sorooshian was born in 1964 and is certified in Pharmaceutical Medicine. He has a Medical degree from the University of Edinburgh and has undergone postgraduate training in anesthesiology.
“We look forward to welcoming Shaw to Moberg Pharma. He will be joining the company in a highly exciting stage as we approach phase 3-results for MOB-015, where he will be adding valuable experience from the development, launch and commercialization of novel treatments”, says Peter Wolpert, CEO Moberg Pharma.
Kjell Rensfeldt will be retiring during the fall but will continue to serve as Senior Advisor to Moberg Pharma on a part-time basis.
